XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.3
JOINT VENTURE (Tables)
 9 Months Ended
Sep. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]  
Schedule of Reconciliation of Direct Payments on Behalf of Joint Venture A reconciliation of amounts included within this footnote to captions in the consolidated statements of cash flows for the nine months ended September 30, 2023 and 2022 follows (in thousands):
Nine Months Ended
September 30,
2023 2022
Payment of TeraWulf 50% share of Bitmain deposits
$— $(11,402)
Investments in joint venture related to direct payments made on behalf of joint venture— (11,402)
Direct investments in joint venture and payments made on plant and equipment contributed to joint venture(2,845)(26,395)
Investments in joint venture, including direct payments made on behalf of joint venture$(2,845)$(37,797)
Payment of Talen 50% share of Bitmain deposits
$— $(11,402)
Other reimbursable payments— (339)
Reimbursable payments for deposits on plant and equipment made on behalf of joint venture or a joint venture partner$— $(11,741)
Talen reimbursement of 50% share of Bitmain deposits
$— $11,402 
Other reimbursable payments— 314 
Reimbursement of payments for deposits on plant and equipment made on behalf of joint venture or a joint venture partner$— $11,716 
Schedule of Interest in Variable Interest Entity and Maximum Exposure The table below summarizes the Company’s interest in Nautilus and the Company’s maximum exposure to loss as a result of its involvement with the VIE as of September 30, 2023 (in thousands, except for percentages):
% Initial
Investment		Additional
Investment, Net		Net loss
Inception
to Date		Company’s
Variable
Interest in
Entity		Commitment to
Future
Additional
Contributions
(1)		Company’s
Maximum
Exposure to Loss
in Entity (2)
EntityOwnership
Nautilus25.0 %$18,000 $117,420 $29,863 $105,557 $— $105,557 
(1)The Members may mutually agree on changes to the Nautilus facility, which could increase the amount of contributions the Company is required to provide. The Members may seek alternate financing for the Nautilus facility, which could reduce the amount of investments each Member may be required to provide.
(2)The maximum exposure at September 30, 2023 is determined by adding the Company’s variable interest in the entity and any explicit or implicit arrangements that could require the Company to provide additional financial support. The amount represents the contractually required capital contributions of the Company which were required for the initial phase of the Nautilus facility buildout.
Equity Method Investments The
condensed results of operations for the three and nine months ended September 30, 2023 and 2022 and the condensed financial position as of September 30, 2023 and December 31, 2022 of Nautilus are summarized below (in thousands):
Three Months Ended
September 30, (1)		Nine Months Ended
September 30, (1)
2023202220232022
Condensed statement of operations information:  
Revenue$29,106 $— $70,929 $— 
Operating expense27,619 2,909 67,646 6,654 
Net income (loss)$1,487 $(2,909)$3,283 $(6,654)
September 30, 2023 (1) December 31, 2022 (1)
Condensed balance sheet information:  
Current assets$14,876 $28,986 
Noncurrent assets182,977 154,552 
Total assets$197,853 $183,538 
Current liabilities$13,981 $12,864 
Noncurrent liabilities27,641 — 
Equity156,231 170,674 
Total liabilities and equity$197,853 $183,538 
(1)The condensed statement of operations information for the three and nine months ended September 30, 2023 and 2022 and the condensed balance sheet information as of September 30, 2023 and December 31, 2022 reflect the impact of the Talen-estimated fair value measurements of Nautilus which, resulting from the application of ASC 805 “Business Combinations,” have been pushed down to the books and records of Nautilus by Talen, as discussed above. The Company’s basis in the assets and liabilities of Nautilus continue to be recorded at historical value on the accompanying consolidated balance sheets.